Onset of cardiac iron loading in pediatric patients with thalassemia major

John C Wood1, Raffaella Origa, Annalisa Agus

  • 1Division of Cardiology, Mailstop 34, Children's Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. jwood@chla.usc.edu

Haematologica
|April 17, 2008
PubMed

Insights

Cardiac iron screening in thalassemia major patients is best timed by age and transfusion history, not just iron levels. Younger children (under 9.5 years) rarely show cardiac iron, suggesting later screening is often appropriate.

Area of Science:

  • Pediatric Cardiology
  • Medical Imaging
  • Hematology

Background:

  • Thalassemia major patients require frequent blood transfusions, leading to iron overload.
  • Cardiac iron loading is a major cause of morbidity and mortality in these patients.
  • Early detection of cardiac iron is crucial for timely intervention.

Purpose of the Study:

  • To determine the optimal timing for cardiac iron screening using magnetic resonance imaging (MRI) in pediatric patients with thalassemia major.
  • To evaluate the relationship between patient age, transfusional iron burden, and cardiac iron levels.
  • To assess the predictive value of liver iron and ferritin levels for cardiac iron loading.

Main Methods:

  • Retrospective review of cardiac T2* assessments in 77 thalassemia major patients aged 2.5 to 18 years.
  • Analysis of cardiac iron detection rates based on age groups.
  • Correlation of cardiac iron with transfusional iron history, liver iron, and ferritin levels.

Main Results:

  • No cardiac iron was detected in patients younger than 9.5 years.
  • Cardiac iron was present in 36% of patients aged 15-18 years (odds ratio of 1.28 per year).
  • All patients with cardiac iron had received at least 35 grams of transfusional iron; liver iron and ferritin did not predict cardiac iron.

Conclusions:

  • Cardiac iron screening timing in thalassemia major should prioritize age and transfusional burden over general iron overload markers.
  • MRI screening can be deferred until age 8 if chelation therapy started at birth and anesthesia is not required.
  • Patients with suboptimal chelation, higher transfusion needs, or later transfusion initiation require earlier screening.

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...